In a phase 2 trial of 34 adults with hereditary angioedema, oral deucrictibant prophylaxis cut monthly attack rate over 12 weeks vs placebo (0.40 with 20 mg and 0.30 with 40 mg vs 1.93; reductions 79.2% and 84.5%), with no serious adverse events.
RCTn = 34
Aygören-Pürsün et al. Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial